- Medical device company Integra LifeSciences ( NASDAQ: IART ) on Tuesday tightened its previously provided guidance for Q4 revenue to a range of $397M to $398M.
- The company anticipated that its Q4 adj. EPS would be above the high end of its previous outlook of $0.87 to $0.91.
- The consensus revenue estimate for Q4 is $397.51M while the EPS estimate is $0.89.
- IART similarly tightened its previously provided guidance for FY 2022 revenue to a range of $1.557B to $1.558B.
- FY 2022 adj. EPS is expected to be above the high of end of its previous outlook of $3.29 to $3.33.
- The consensus revenue estimate for FY 2022 is $1.56B while the EPS estimate is $3.30.
- IART also reiterated its plan to start a $150M share buyback program in early 2023.
- Integra LifeSciences ( IART ) stock earlier closed -0.2% at $57.61.
For further details see:
Integra LifeSciences sees Q4 revenue in-line with expectations